跳至主要内容
临床试验/CTRI/2024/05/067236
CTRI/2024/05/067236已完成不适用

A preliminary investigation of the safety and effectiveness of oral probiotics supplementation for reducing the risk of kidney stone in adults with recurrent kidney stone colic or acute episode of colicky pain: An open-label, single-arm, prospective, interventional, proof-of-science study.

Meteoric Biopharmaceuticals Pvt. Ltd.2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2024年5月20日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12
试验地点
2
主要终点
1.Evaluate the effect of the test treatment in term of change in the colicky pain determined using the VAS scoring.

研究概览

简要总结

A Preliminary Investigation of the Safety and Effectiveness of Oral Probiotics Supplementation for Reducing the Risk of Kidney Stone in Adults with Recurrent Kidney Stone Colic or Acute Episode of Colicky Pain: An Open-Label, Single-Arm, Prospective, Interventional, Proof-of-Science Study. Maximum 12 subjects will be enrolled to complete the study. Duration will be of approximately 14 days which includes 2 visits. 

Visit 01 [Day 01]: Screening, baseline evaluations, enrolment and treatment dispensing.

Visit 02 [Day 14]: Treatment End, Final Evaluations.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 55.00 Year(s)(—)
性别
All

入选标准

  • 1.The subject is an adult aged between 18 to 55 years old.
  • 2.The subject has a history of recurrent kidney stone colic or acute episode of colicky pain on clinical examination by Physician.
  • 3.The subject is willing to provide written informed consent and comply with study procedures, including overnight stay for 24 hours at the study centre during both visits.
  • 4.The subject is willing to abide by the study protocol and restrictions, including abstaining from using any other oral or topical treatments for kidney stone colic during the study period.
  • 5.The subject is in a stable medical condition, not requiring immediate intervention or hospitalization.
  • a.Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device/injection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence).
  • b.Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration.

排除标准

  • 1 Subject has a history of severe renal impairment or chronic kidney disease.
  • 2 Subject is pregnant/lactating, or is planning on become pregnant during the course of the study.
  • 3 Subject has presence of significant medical or psychiatric conditions that may interfere with study participation or interpretation of results.
  • 4 Subject has a history of substance abuse or dependence.
  • 5 Subject has severe systemic complications of viral infections, cardiovascular disorders, neurological disorders, renal disorders, or autoimmune disorders.
  • 6 Subject has participated in clinical studies or received any investigational agent in the previous 30 days.
  • 7 Subject has any condition that, in the judgement of investigator, would compromise the safety of subject or study integrity.

结局指标

主要结局

1.Evaluate the effect of the test treatment in term of change in the colicky pain determined using the VAS scoring.

时间窗: 1. Scoring on Day 01 (before administration) for baseline, and post-dosage on Day 14. | 2. On Day 01 (before administration) for baseline, and post-dosage on Day 14.

2.Evaluate the effect of the test treatment in terms of changes in urinalysis parameters such as Urine Calcium, Sodium, Oxalate, pH, and R/M, after 24h-urine collection

时间窗: 1. Scoring on Day 01 (before administration) for baseline, and post-dosage on Day 14. | 2. On Day 01 (before administration) for baseline, and post-dosage on Day 14.

次要结局

  • 1.Evaluate the safety of the test treatment in terms of abnormal changes in blood test parameters such as CBC, Serum Creatinine, SGPT, SGOT.(On Day 01 (before administration) for baseline, and post-dosage on Day 14.)

研究者

发起方
Meteoric Biopharmaceuticals Pvt. Ltd.
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Hardik Yadav

NovoBliss Research Private Limited

研究点 (2)

Loading locations...

相似试验